Precision Optics at Lytham Partners: Manufacturing Drives Growth

Precision Optics Corporation (POCI) announced a strategic shift at the Lytham Partners Fall 2025 Investor Conference, transitioning its primary revenue source from product development to manufacturing, driven by two key programs moving into production. The company projects a 30% revenue increase to $25 million in fiscal year 2026 from $19 million in FY2025, supported by a record $18 million backlog. Despite initial gross margin pressures in FY2025 due to production ramp-up, POCI anticipates a recovery to 30% in FY2026 and a return to positive adjusted EBITDA, signaling improved financial performance and market visibility.

Analysis

Precision Optics Corporation (POCI) is at a significant inflection point, transitioning from a development-focused entity to a manufacturing-driven business. The firm has issued its first-ever annual guidance, forecasting a more than 30% revenue increase to $25 million for fiscal year 2026, up from approximately $19 million in fiscal 2025. This projection is substantiated by a record backlog of nearly $18 million and strong momentum from two key programs—a single-use cystoscopy device and an aerospace application—that have recently entered production. The aerospace program's revenue, in particular, demonstrated rapid acceleration, growing to nearly $2 million in Q4 2025 alone. While this accelerated ramp-up has temporarily compressed gross margins in fiscal 2025, management expresses confidence in resolving these startup challenges, guiding for a margin recovery to an annualized 30% in fiscal 2026 and a return to positive adjusted EBITDA. The long-term growth strategy hinges on replenishing the development pipeline via its new Unity platform, with the goal of bringing two to three new programs into production annually.

Key Decisions for Investors

• Investors should recognize the company's strategic inflection point, as the shift to a manufacturing-led model, supported by a $25 million revenue forecast for fiscal 2026 and a record $18 million backlog, signals a strong growth trajectory.
• It is critical to monitor the company's ability to achieve its guided 30% gross margin in fiscal 2026, as this will validate that recent production ramp-up challenges are transient and that the business model is scaling profitably.
• Beyond the near-term revenue ramp, focus should be on the success of the Unity platform in securing new development programs, as the ability to consistently transition two to three new products into manufacturing annually is essential for sustaining long-term growth.
• Consider the growing contribution from the defense and aerospace sector, which demonstrated significant quarterly acceleration, as a key diversification and growth vector beyond the core medical device market.